B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.

Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAF(V600E) oncogene. These tissue-specific compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30% of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways.

[1]  R. Cardiff,et al.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. , 2012, Cancer research.

[2]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[3]  B. Nelkin,et al.  Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer , 2011, Clinical Cancer Research.

[4]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[5]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[6]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[7]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[8]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[9]  G. Zhu,et al.  KRAS and BRAF mutations in prostate carcinomas of Chinese patients. , 2010, Cancer genetics and cytogenetics.

[10]  H. Stein,et al.  Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. , 2010, Cancer cell.

[11]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[12]  N. Dhomen,et al.  BRAF signaling and targeted therapies in melanoma. , 2009, Hematology/oncology clinics of North America.

[13]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[14]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[15]  L. Chin,et al.  BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma , 2008, PloS one.

[16]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[17]  T. Giordano,et al.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells , 2008, Oncogene.

[18]  J Khan,et al.  The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.

[19]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[20]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[21]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[22]  E. Gelmann,et al.  R E V Ie W a Rt I C L E , 2022 .

[23]  J. Blenis,et al.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1 , 2008, Proceedings of the National Academy of Sciences.

[24]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[25]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[26]  Kyung Chul Moon,et al.  BRAF and KRAS mutations in prostatic adenocarcinoma , 2006, International journal of cancer.

[27]  W. Gerald,et al.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.

[28]  Robert R. Klein,et al.  Expression of mTOR signaling pathway markers in prostate cancer progression , 2006, The Prostate.

[29]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[30]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[31]  Duonan Yu,et al.  Functional Validation of Genes Implicated in Lymphomagenesis: An in Vivo Selection Assay Using a Myc‐Induced B‐Cell Tumor , 2005, Annals of the New York Academy of Sciences.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Gioeli.  Signal transduction in prostate cancer progression. , 2005, Clinical science.

[34]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[35]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[36]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[37]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[38]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[39]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[40]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[41]  M. Groszer,et al.  Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.

[42]  U. Weidle,et al.  The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.

[43]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[44]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[45]  R. Cardiff,et al.  Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.

[46]  M. McMahon,et al.  Complementation of Defective Colony-Stimulating Factor 1 Receptor Signaling and Mitogenesis by Raf and v-Src , 1999, Molecular and Cellular Biology.

[47]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[48]  J. Troppmair,et al.  Regulation of c-myc expression by Ras/Raf signalling , 1998, Oncogene.

[49]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[50]  P. Pandolfi,et al.  Faithfull modeling of PTEN loss driven diseases in the mouse. , 2010, Current topics in microbiology and immunology.

[51]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[52]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[53]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[54]  E.E. Pissaloux,et al.  Image Processing , 1994, Proceedings. Second Euromicro Workshop on Parallel and Distributed Processing.